Publications

Lancet Oncology

International Rare Cancers Initiative (IRCI)

Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative

Abstracts and Posters

• International Rare Cancers Initiative (577 KB)
• ASCO Meeting Library
• International Rare Cancers Initiative on the NCRI Cancer Conference website

IRCI publication list

We have a compiled a list of publications from existing working groups as well as other external works referring to IRCI. We hope you will find this a useful reference and this list of publications will be available on the IRCI website in due course. If you know of any additional publications, please let us know.

Essential reading for IRCI trialists

Bogaerts J, et al. Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer 2015;51:271-81

More about the formation of the International Rare Cancers Initiative

Keat N, et al. The international rare cancers initiative. J Clin Oncol 2014;32(suppl):e17504
Keat N, et al. International Rare Cancers Initiative. Lancet Oncol 2013;14:109-110
Keat N, et al. International Rare Cancers Initiative (IRCI). ecancer 2013;7:10.3332

Publications from IRCI Working Groups: Gynecological sarcoma

Hensley M, et al. Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study. J Clin Oncol 2018;36(suppl):5505

Publications from IRCI working groups: Penile cancer

Nicholson S, et al. Clinical trial strategy for penis cancer. BJU Int 2014;113:852–3

Publications from IRCI Working Groups: Relapsed/metastatic anal cancer

Eng C, et al. Post-treatment surveillance in locally advanced squamous cell carcinoma (SCCA) of the anal canal: A global subspecialist survey. J Clin Oncol 2016;34(suppl): abstr 573

Sclafani F, et al. InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease. J Clin Oncol 2015;33(suppl): abstr TPS792

Publications from IRCI Working Groups: Rare skin cancer

Khoja L, et al. Meta-analysis of phase II trials in metastatic uveal melanoma (MUM) to determine progression-free (PFS) and overall survival (OS) benchmarks for future phase II trials: An irci-ocular melanoma initiative. J Clin Oncol 2016;34(suppl):abstr 9567

Luke J, et al. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res 2015;28:135–47

Publications from IRCI Working Groups: Salivary gland cancer

Locati L, et al. 2018. Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578). J Clin Oncol 2018;36(suppl):abstr TPS6099

Publications from IRCI Working Groups: Small bowel adenocarcinoma

Pedersen K, et al. Trial in progress: A multicenter phase II study of pembrolizumab in patients with advanced small bowel adenocarcinomas. J Clin Oncol 2018;36(suppl):abstrTPS535
Schrock AB, et al. Genomic profiling of small bowel adenocarcinoma: Insights from a comparative analysis with gastric and colorectal cancer and opportunities for targeted therapy. Ann Oncol 2016;27(suppl):613O
Evans T, et al. GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002). J Clin Oncol 2016;34(suppl):abstrTPS4154

External works referring to IRCI

Aparicio T, et al. Small Bowel Adenocarcinoma. Gastroenterol Clin N Am 2016;45:447-57
Blay J-Y, et al. The value of research collaborations and consortia in rare cancers. Lancet Oncol 2016;17:e63
Crook, J. Radiotherapy approaches for locally advanced penile cancer: neoadjuvant and adjuvant. Curr Opin Urol 2017;27:62-7
DeSantis C, et al. The Burden of Rare Cancers in the United States. Ca Center J Clin 2018;67:261-72
Detterbeck F, Korst R. The International Thymic Malignancy Interest Group Thymic Initiative: A State-of-the-Art Study of Thymic Malignancies. Semin Thoracic Surg 2014;26:317–22
Halfdanarson T, et al. Establishing a standard of care for small bowel adenocarcinomas: challenges and lessons learned. Oncologist 2012;17:1133
Komatsubara K, Carvajal R. The promise and challenge of rare cancer research. Lancet Oncol 2016;17:136-7
Pillai R, et al. Rare Cancers: Challenges and Issues. Indian J Med Res 2017;145:17-27
Raghav K, et al. Small bowel adenocarcinomas – existing evidence and evolving paradigms. Nat Rev Clin Oncol 2013;10:534–44
Ray-Coquard I, et al. Improving treatment results with reference centres for rare cancers: Where do we stand? Eur J Cancer 2017;77:90-8
Roy A, et al. Uncommon Anal Neoplasms. Surg Oncol Clin N Am 2017;26:143-61
Schott A, et al. The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers. Semin Oncol 2015;42:731-9
Sclafani F, et al. Systemic Therapies for Advanced Squamous cell Anal Cancer. Curr Onc Reports 2018;20:53
Sclafani F, et al. Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. Oncologist 2017;22:402-8
Scott L. Salivary Gland Cancers: The Challenges of Progress in Rare Tumors. Oncology 2015;29:781-2